Key facts
- Notable investors include Ronggu Biotechnology, Wosheng Investment, Xinglian Future.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Longsun Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Longsun Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Longsun Bio
Manufacturer of cell therapy technologies designed to support the development and clinical translation of regenerative and immune-based therapeutics. The company offers CAR-T research capabilities, long-acting NK cell development, and clinical-grade stem and immune cell preparation services, enabling hospitals and biotechnology researchers to access high-quality cellular therapeutics with greater reliability and translational potential
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2025
- Website
- longsun-bio.com/
- Ownership
- Privately Held (backing)
Longsun Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Longsun Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Longsun Bio in its N-PORT filings yet. We sweep new filings monthly.